191 related articles for article (PubMed ID: 35676472)
61. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
[TBL] [Abstract][Full Text] [Related]
62. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
63. Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.
Liu X; Simon JM; Xie H; Hu L; Wang J; Zurlo G; Fan C; Ptacek TS; Herring L; Tan X; Li M; Baldwin AS; Kim WY; Wu T; Kirschner MW; Gong K; Zhang Q
Mol Cell; 2020 Mar; 77(6):1294-1306.e5. PubMed ID: 32023483
[TBL] [Abstract][Full Text] [Related]
64. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
65. Prolyl Hydroxylase 3 Knockdown Accelerates
Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686
[TBL] [Abstract][Full Text] [Related]
66. Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2α expression.
Nagaprashantha LD; Talamantes T; Singhal J; Guo J; Vatsyayan R; Rauniyar N; Awasthi S; Singhal SS; Prokai L
PLoS One; 2013; 8(8):e71654. PubMed ID: 23940778
[TBL] [Abstract][Full Text] [Related]
67. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract][Full Text] [Related]
68. VHL and HIF signalling in renal cell carcinogenesis.
Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP
J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241
[TBL] [Abstract][Full Text] [Related]
69. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
[TBL] [Abstract][Full Text] [Related]
70. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
71. Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression.
Maynard MA; Evans AJ; Shi W; Kim WY; Liu FF; Ohh M
Cell Cycle; 2007 Nov; 6(22):2810-6. PubMed ID: 17998805
[TBL] [Abstract][Full Text] [Related]
72. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
73. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.
Rohan SM; Xiao Y; Liang Y; Dudas ME; Al-Ahmadie HA; Fine SW; Gopalan A; Reuter VE; Rosenblum MK; Russo P; Tickoo SK
Mod Pathol; 2011 Sep; 24(9):1207-20. PubMed ID: 21602815
[TBL] [Abstract][Full Text] [Related]
74. Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma.
Ricketts CJ; Linehan WM
Cancer Discov; 2017 Nov; 7(11):1221-1223. PubMed ID: 29097620
[TBL] [Abstract][Full Text] [Related]
75. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.
Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO
Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212
[TBL] [Abstract][Full Text] [Related]
76. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals.
Wu TK; Wei CW; Pan YR; Hsu RJ; Wu CY; Yu YL
Sci Rep; 2019 Mar; 9(1):3207. PubMed ID: 30824757
[TBL] [Abstract][Full Text] [Related]
77. Sensitivity of
Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
[TBL] [Abstract][Full Text] [Related]
78. The m
Xiao Y; Thakkar KN; Zhao H; Broughton J; Li Y; Seoane JA; Diep AN; Metzner TJ; von Eyben R; Dill DL; Brooks JD; Curtis C; Leppert JT; Ye J; Peehl DM; Giaccia AJ; Sinha S; Rankin EB
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21441-21449. PubMed ID: 32817424
[TBL] [Abstract][Full Text] [Related]
79. VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression.
Ji J; Xu Y; Xie M; He X; Ren D; Qiu T; Liu W; Chen Z; Shi W; Zhang Z; Wang X; Wang W; Ma J; Qian Q; Jing A; Ma X; Qin J; Ding Y; Geng T; Yang J; Sun Z; Liu W; Liu S; Liu B
Cell Death Dis; 2023 Feb; 14(2):83. PubMed ID: 36739418
[TBL] [Abstract][Full Text] [Related]
80. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
